OTEurope

Bevacizumab improves success rate of augmented trabeculectomy for neovascular glaucoma in young diabetic patients

May 9, 2008

The addition of bevacizumab (Avastin) to trabeculectomy improves the success rate of IOP control, particularly in young diabetic patients with neovascular glaucoma (NVG), according to a study published online, ahead of print, by Eye.

Related Videos

Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase

2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent

Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in

Investigating the effects of canaloplasty on corneal epithelium

Related Content

Federal investment and regulatory benefits draw biotech firms to Switzerland

Preservative-free latanoprost as effective as BAK-preserved latanoprost

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Late spring heatwave poses vision risk to populations across Europe

Stating the facts about combination myopia management treatments

WHO validates Benin and Mali for eliminating trachoma as public health problem

Federal investment and regulatory benefits draw biotech firms to Switzerland

Preservative-free latanoprost as effective as BAK-preserved latanoprost

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Late spring heatwave poses vision risk to populations across Europe

Stating the facts about combination myopia management treatments

WHO validates Benin and Mali for eliminating trachoma as public health problem

Federal investment and regulatory benefits draw biotech firms to Switzerland

Preservative-free latanoprost as effective as BAK-preserved latanoprost

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Late spring heatwave poses vision risk to populations across Europe

Stating the facts about combination myopia management treatments

WHO validates Benin and Mali for eliminating trachoma as public health problem

Related Content

An airport departure board shows a flight to Geneva is boarding. Image credit: ©WD Stockphotos – stock.adobe.com

Federal investment and regulatory benefits draw biotech firms to Switzerland

The country is home to 20% of biotechs headquartered in Europe.

Preservative-free latanoprost as effective as BAK-preserved latanoprost

Preservative-free latanoprost as effective as BAK-preserved latanoprost

Therapeutic has fewer adverse effects in patients with POAG and OHT, study results show

UK patients with vision loss confused by ‘disjointed’ benefits registration system

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Accessibility obstacles could prevent those with sight loss from receiving support and care.

Late spring heatwave poses vision risk to populations across Europe

Late spring heatwave poses vision risk to populations across Europe

What ophthalmologists want patients to know ahead of UK bank holiday.

Stating the facts about combination myopia management treatments

Stating the facts about combination myopia management treatments

Growing evidence supports dual therapy to slow progression.

WHO validates Benin and Mali for eliminating trachoma as public health problem

WHO validates Benin and Mali for eliminating trachoma as public health problem

The countries join 15 other nations that have eliminated the disease.

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.